Prof. PeptideProf. Peptide
Guide

Ozempic Dosage in 2026: The FDA Label Schedule

Ozempic (semaglutide) is a once-weekly injection approved for type 2 diabetes. Its label starts at 250 mcg weekly for 4 weeks, then 500 mcg, and allows steps to 1,000 mcg (1 mg) and a 2,000 mcg (2 mg) maximum, each after at least 4 weeks, if more glycemic control is needed. It has no weight-loss indication.

Topic: Reading Ozempic’s FDA prescribing information

Audience: Anyone comparing a dosing schedule against its source

Reading time: 7–9 minutes

Not affiliated with Novo Nordisk. Prof. Peptide is not affiliated with, endorsed by, or sponsored by Novo Nordisk. Ozempic is a registered trademark of Novo Nordisk A/S. This page reports what Novo Nordisk’s own prescribing information and FDA’s own publications state; it does not sell, ship, or recommend the branded product.

What Ozempic is

Ozempic is a brand name. Its active ingredient is semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist manufactured by Novo Nordisk. The label states Ozempic is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus, to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease, and to reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease. None of the three is a weight-loss indication.

“Ozempic” now names two products. Besides the injection, DailyMed carries a tablet label titled for RYBELSUS and OZEMPIC tablets (effective January 30, 2026), indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. This page reads the injection label; the tablet’s own schedule is a separate document.

Semaglutide is also sold under other brand names, at different doses, for different indications — Wegovy (weight reduction, cardiovascular risk reduction and MASH) and Rybelsus (an oral form, type 2 diabetes only) are the same molecule with different labels. The Prof. Peptide semaglutide profile covers how the three relate, the mechanism, and the published trial evidence across all three. This page reads Ozempic’s own label specifically, since its dosing schedule, indications, and cited trials are not identical to Wegovy’s or Rybelsus’s. How the tablets compare with the injection is set out in semaglutide pills vs injection.

What the label specifies

The table below is Ozempic’s recommended dosage as stated in section 2.2 of its prescribing information — Novo Nordisk, OZEMPIC (semaglutide) injection prescribing information, DailyMed setid adec4fd2-6858-4c99-91d4-531f5f2a2d79, effective June 1, 2026.

StepDosageAs specified by the label
Initiation250 mcg once weeklyFor 4 weeks. The label states this dosage is to reduce the risk of gastrointestinal adverse reactions during initiation, not for glycemic control.
First increase500 mcg once weeklyAfter 4 weeks on the 250 mcg dosage.
Second increase (if needed)1,000 mcg (1 mg) once weeklyAfter at least 4 weeks on the 500 mcg dosage, if additional glycemic control is needed.
Maximum dosage (if needed)2,000 mcg (2 mg) once weeklyAfter at least 4 weeks on the 1,000 mcg (1 mg) dosage, if additional glycemic control is needed.
Chronic kidney disease maintenance1,000 mcg (1 mg) once weeklyAfter at least 4 weeks on the 500 mcg dosage — the label states this dosage specifically to reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in patients with type 2 diabetes and chronic kidney disease.

The label states the maximum recommended dosage is 2,000 mcg (2 mg) once weekly. Under section 2.1, a missed dose is administered within 5 days; past that window, it is skipped and the regular weekly schedule resumes.

Section 2.1 states that Ozempic is administered by subcutaneous injection in the abdomen, thigh, or upper arm, with a different site used each week within the same body region. Section 12.3 gives semaglutide a half-life of approximately 1 week: it is present in the circulation for about 5 weeks after the last dose, and steady-state exposure is reached after 4 to 5 weeks of once-weekly dosing.

Dosage forms and strengths (section 3) list single-patient-use pens and single-dose prefilled syringes at 0.25 mg, 0.5 mg, 1 mg, and 2 mg per injection — the label’s strengths are per-injection doses delivered by a pre-filled device, so the label states no reconstitution math anywhere. The peptide dosage calculator works out how much bacteriostatic water to add to a research-grade vial and how many syringe units a given amount takes. It does not set a dose.

How do clinics prescribe Ozempic?

Clinics that prescribe Ozempic describe it as a type 2 diabetes drug that may be prescribed for weight outside its label. One states plainly that “Ozempic® is not FDA-approved for weight loss” and that its clinicians may prescribe it as part of a weight-management program where they judge it appropriate. Another describes Ozempic and Wegovy as two approved Novo Nordisk medicines that both use semaglutide.

No clinic Ozempic dosing table was found after searching the eight largest telehealth companies: four have no Ozempic page, and the four that do publish no Ozempic-specific doses. The label’s ladder above is the only published Ozempic schedule. Clinic schedules for compounded semaglutide are on the semaglutide dosing guide and the semaglutide profile.

What the trials administered

Section 14 of the label (Clinical Studies) names the trials behind Ozempic’s approved indications. The three below are the ones the label cites by name and registry number for the dosing and outcomes discussed on this page. Each is graded against Prof. Peptide’s standing citation convention — a claim is attributed when a marker resolves to a named, checkable primary source, rather than left as an unmarked figure. All three grade as attributed: each is named in the label itself, with a registry number checkable against ClinicalTrials.gov independent of the label.

Monotherapy trial (NCT02054897)

30-week, double-blind, placebo-controlled

Arms: Placebo (N=129), OZEMPIC 500 mcg (N=128), OZEMPIC 1,000 mcg (1 mg) (N=130) — patients with type 2 diabetes inadequately controlled by diet and exercise

Endpoint reported: Change in HbA1c from baseline at week 30: −0.1% (placebo) vs. −1.4% (500 mcg) vs. −1.6% (1,000 mcg, 1 mg); difference from placebo statistically significant at p<0.0001 for both doses.

Attributed — cited directly in the label's own Clinical Studies section (14.1), primary source open below.

SUSTAIN 6 (NCT01720446)

Multi-center, multi-national, placebo-controlled, double-blind cardiovascular outcomes trial

Arms: Placebo (N=1,649), OZEMPIC (N=1,648) — patients with type 2 diabetes and established atherosclerotic cardiovascular disease, median observation 2.1 years

Endpoint reported: Hazard ratio for time to first major adverse cardiovascular event (MACE — cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke): 0.74 (95% CI: 0.58, 0.95) vs. placebo.

Attributed — cited directly in the label's Clinical Studies section (14.2) and in the boxed indication for cardiovascular risk reduction.

FLOW (NCT03819153)

Placebo-controlled kidney and cardiovascular outcomes trial

Arms: Placebo (N=1,766), OZEMPIC 1,000 mcg (1 mg) (N=1,767) — patients with type 2 diabetes and chronic kidney disease

Endpoint reported: Hazard ratio for the composite endpoint (≥50% sustained eGFR decline, sustained eGFR <15 mL/min/1.73m², chronic renal replacement therapy, or renal/cardiovascular death): 0.76 (95% CI: 0.66, 0.88), p=0.0003.

Attributed — cited directly in the label's Clinical Studies section and underlying the kidney-disease indication added to the label, with a registry number checkable against ClinicalTrials.gov independent of the label.

Wegovy’s label cites a different trial program (the STEP trials, for chronic weight management) at different doses and a different indication. Those figures belong to Wegovy’s own label, not Ozempic’s, even though both products share the same active ingredient — the semaglutide profile covers the STEP program directly.

The label’s warnings and adverse events

Boxed warning: risk of thyroid C-cell tumors

The label states: “It is unknown whether OZEMPIC causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans”; the human relevance of the tumor finding behind the warning has not been determined.

The label states Ozempic is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), and instructs counseling patients on the potential risk and on symptoms such as a mass in the neck, dysphagia, dyspnea, or persistent hoarseness.

Section 6 of the label lists eight other warnings discussed elsewhere in the prescribing information: acute pancreatitis, diabetic retinopathy complications, hypoglycemia with concomitant insulin secretagogues or insulin, acute kidney injury due to volume depletion, severe gastrointestinal adverse reactions, hypersensitivity reactions, acute gallbladder disease, and pulmonary aspiration during general anesthesia or deep sedation. The label states the most common adverse reactions reported in ≥5% of Ozempic-treated patients are nausea, vomiting, diarrhea, abdominal pain, and constipation.

Table 1 of the label reports adverse reaction rates from two placebo-controlled trials (521 patients, mean exposure 32.9 weeks), for reactions occurring in ≥5% of Ozempic-treated patients:

Adverse reactionPlacebo (N=262)Ozempic 500 mcg (N=260)Ozempic 1,000 mcg (1 mg) (N=261)
Nausea6.1%15.8%20.3%
Vomiting2.3%5%9.2%
Diarrhea1.9%8.5%8.8%
Abdominal pain4.6%7.3%5.7%
Constipation1.5%5%3.1%

Compounding and research-grade semaglutide

Ozempic’s prescribing information does not mention compounding. The word does not appear anywhere in the label. Everything above this section describes a prescription drug product, manufactured by Novo Nordisk and dispensed by a pharmacy against a prescription.

Research-grade semaglutide, of the kind sold by the vendors Prof. Peptide tracks elsewhere on this site, is neither the branded product described above nor a pharmacy-compounded version of it. It is sold labeled for research use, not for human administration, and it is not dispensed against a prescription.

Separately from the branded label, FDA has published its own position on compounded semaglutide. Its April 1, 2026 statement on compounding, once the national GLP-1 supply stabilized, describes the conditions under which a compounded drug can lawfully be exempt under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act, and states FDA’s position that a compounded product is treated as an unlawful copy of a commercially available drug when it shares the same active ingredient, a similar or easily substitutable strength, and the same route of administration — unless a prescriber documents a significant difference for an individual patient.

On April 30, 2026, FDA announced it is proposing to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list entirely, stating it “did not identify a clinical need for outsourcing facilities to compound semaglutide, tirzepatide, and liraglutide from bulk drug substances.” The public comment period on that proposal closed, and FDA has not published a final determination.

FDA also writes that the salt forms some compounders sell, semaglutide sodium and semaglutide acetate, are different active ingredients from those in the approved drugs, and that it is “not aware of any lawful basis for their use in compounding.” It reports adverse events, some requiring hospitalization, linked to dosing errors with compounded injectable semaglutide, and adverse events in patients prescribed compounded semaglutide or tirzepatide “in doses beyond what is in the FDA-approved drug label,” including a faster titration schedule.

None of this changes what the label above states, and none of it describes Prof. Peptide’s vendors as compounding pharmacies — they are not. It is published here because a reader comparing a branded dosing schedule against a research-grade product should be able to see, in one place, that the two are governed by different rules, and that the regulatory status of compounded semaglutide is itself unsettled and separate from both.

FAQ

Is Ozempic the same as semaglutide?
Ozempic is a brand name. The active ingredient is semaglutide, a GLP-1 receptor agonist made by Novo Nordisk. The same molecule is sold under other brand names for other indications and doses — see the semaglutide profile for how Ozempic, Wegovy, and Rybelsus relate to one another.
What is the starting dose on the Ozempic label?
The prescribing information specifies an initiation dosage of 250 mcg injected subcutaneously once weekly for 4 weeks, then an increase to 500 mcg once weekly. The 250 mcg dose is described in the label as being for treatment initiation, not for glycemic control.
What is the maximum Ozempic dose?
The label states a maximum recommended dosage of 2,000 mcg (2 mg) once weekly, reached only after at least 4 weeks each at the 500 mcg and 1,000 mcg (1 mg) dosages.
What happens if a dose is missed?
Under the label, a missed dose is administered within 5 days. If more than 5 days have passed, the missed dose is skipped and the regular weekly schedule resumes.
Does Ozempic carry a boxed warning?
Yes. The label's boxed warning covers the risk of thyroid C-cell tumors: it states that it is unknown whether Ozempic causes them in humans, because their human relevance has not been determined. The label contraindicates Ozempic in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.
Is Ozempic approved for weight loss?
No. The injection label's three indications are all for adults with type 2 diabetes: glycemic control, reducing major cardiovascular events in those with established cardiovascular disease, and reducing kidney decline and cardiovascular death in those with chronic kidney disease. Clinics that prescribe it state the same: one writes that Ozempic is not FDA-approved for weight loss and may be prescribed by its clinicians where they judge it appropriate. Wegovy is the semaglutide label for weight reduction.
Is there an Ozempic pill?
Yes. DailyMed now carries a tablet label titled for RYBELSUS and OZEMPIC tablets, indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. It is a separate label from the injection, and its tablet schedule is not covered on this page.
How long does Ozempic stay in the body?
The label gives semaglutide a half-life of approximately 1 week and states it is present in the circulation for about 5 weeks after the last dose; steady-state exposure is reached after 4 to 5 weeks of once-weekly dosing.
Is compounded or research-grade semaglutide the same as Ozempic?
No, and the label does not address the question either way — it never mentions compounding. Ozempic is a prescription product, dispensed by a pharmacy against a prescription, manufactured and labeled by Novo Nordisk. See the compounding and research-grade section on this page for how FDA's own compounding rules and the vendors Prof. Peptide tracks relate to that.

References

  1. Novo Nordisk. RYBELSUS and OZEMPIC (oral semaglutide) tablets — prescribing information. DailyMed, setid 27f15fac-7d98-4114-a2ec-92494a91da98, effective 2026-01-30; read 2026-11-06. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98
  2. Ivím Health. Ozempic. Read 2026-11-06. https://www.ivimhealth.com/ozempic/
  3. Pru. Semaglutide vs Ozempic and Wegovy. Read 2026-11-06. https://joinpru.com/blog/semaglutide-vs-ozempic-wegovy
  4. U.S. Food and Drug Administration. FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. Content current as of 2026-10-01; read 2026-11-04. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
  5. Novo Nordisk. OZEMPIC (semaglutide) injection, for subcutaneous use — prescribing information. DailyMed, setid adec4fd2-6858-4c99-91d4-531f5f2a2d79, effective 2026-06-01; read 2026-11-06. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79
  6. U.S. Food and Drug Administration. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize. Drug Alerts and Statements, 2026-04-01. https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize
  7. U.S. Food and Drug Administration. FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List. Press Announcements, 2026-04-30. https://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list
  8. Marso SP, Bain SC, Consoli A, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN 6, NCT01720446). N Engl J Med. 2016;375:1834-1844. https://www.nejm.org/doi/full/10.1056/NEJMoa1607141
  9. ClinicalTrials.gov. Monotherapy trial of once-weekly semaglutide in type 2 diabetes, NCT02054897. https://clinicaltrials.gov/study/NCT02054897
  10. ClinicalTrials.gov. Effect of Semaglutide Versus Placebo on the Progression of Renal Impairment in Subjects With Type 2 Diabetes and Chronic Kidney Disease (FLOW), NCT03819153. https://clinicaltrials.gov/study/NCT03819153

Affiliate disclosure: Prof. Peptide earns a commission on purchases and sign-ups made through its links and codes, at no extra cost to the buyer. Commissions never decide which vendors are listed, how they are ranked or verified, or what Prof. Peptide concludes.

Checked and updated